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Conclusion* Dynamic dose fractionation HDR-brachytherapy,
as 1st step of preoperative chemo-irradiation, allows to reach
the total tumor regression, which enable further ablastic sur-
gery and relapse-free follow-up.
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Introduction/Background* Platinum in combination with pacli-
taxel (P) and bevacizumab is the standard of care in first-line
recurrent/advanced cervical cancer (Tewari, NEJM 2020). Nin-
tedanib is an oral tyrosine kinase inhibitor targeting, among
others, vascular endothelial growth factor receptor.
Methodology Double-blind phase II randomised study in
patients with first-line recurrent or primary advanced (FIGO
stage IVB) cervical cancer. Patients received carboplatin AUC
5-6 and paclitaxel 175mg/m2 q 3 weeks with oral nintedanib
200 mg BID/placebo. Stratification factor was primary
advanced versus recurrent disease. The primary endpoint was
progression-free survival (PFS) at 1,5 years with at least 87
events and a=0.15, b=80%, one sided, in favor of the nin-
tedanib (N) versus control (C) arm. The study
(NCT02009579) was performed according to the ENGOT
model A.
Result(s)* 120 patients (62 N, 58 C) were randomised
between March 2014 and October 2018. Median follow-up
was 35 months. Baseline characteristics were similar in both
groups (total population: squamous cell carcinoma 62%, prior
radiotherapy 64%, primary advanced 25%, recurrent 75%).
The primary endpoint was met with a PFS at 1.5 years of
15.1% versus 12.8% in favour of the nintedanib arm (p =
0.057). Median overall survival (OS) was 21.7 and 16.4
months for N and C, respectively. Subgroup analysis did not
demonstrate a difference in PFS in the primary advanced set-
ting, but in the recurrent setting the 1 year PFS was 22.8%
and 14.9% for N and C, respectively. Confirmed RECIST
response rate was 48% for N and 39% for C. No new
adverse events were noted for N. However N was associated
with numerically more serious adverse events for anemia and
febrile neutropenia. Discontinuation of chemotherapy was sim-
ilar in both groups. N was discontinued in 3% versus placebo
in 1.6% of the patients. Dose reduction of N was necessary
in 53% of the patients.
Conclusion* The study met its primary endpoint with a pro-
longed PFS in the N arm. No new safety signals were
observed.
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Introduction/Background* Cervical cancer is one of the most
prevalent and leading cause of cancer mortality for women
worldwide. Persistent infection with HPV is associated with
the development of cervical cancer. Although most infections
are cleared by the immune response, the factors related to
persistent infection and carcinogenesis are less well under-
stood. Epigenetic alterations are essential in the development
of many cancers; while aberrant hypermethylation in cervical
carcinogenesis has been identified in several targeted studies,
epigenome-wide exploration has been limited. In this epige-
nome-wide association study (EWAS) we explore differential
DNA methylation signatures associated to CIN3 and Cervical
Cancer, to better understand potential drivers and biomarkers
of cervical carcinogenesis.
Methodology 247 women (119 normal, 74 CIN3/CGIN and
54 cervical cancer) attending gynaecological appointments, cer-
vical screening and oncological treatment between 2014-2020
at English and Greek referral hospitals were recruited. Methyl-
ation signatures were obtained following bisulphite conversion
of DNA extracted from exfoliated cervical cells and sequenced
using the Illumina 850k array data. After normalisaton and
data QC, mixed linear models and a penalised regression were
used to test for independent associations between methylation
CpG sites and case-control status. P-values were Bonferroni
corrected and adjusted for batch, chip, age and HPV status.
Result(s)* 177 CpG sites were strongly assosicated with CIN3
or cervical cancer, as measured by a P-value <5x10-8 and a
gain/loss in methylation of >15% between cases and controls.
Epigenetic signals were located in over 141 unique genes
genome-wide, with a gain in methylation in CIN3 or cancer
cases being more common (n=77/80).
Conclusion* This is potentially the first adequately powered
study to highlight genome-wide epigenetic signatures associated
to carcinoma in situ and cervical cancer. This builds on pre-
vious genetic signals associated with cervical cancer identified
by our group (Bowden et al, Lancet Oncol, 2021). While
around 59 genes were previously reported associations to CIN
or cervical cancer, the remaining 82 signals appear to be
novel. Functional annotation highlighted several genes related
to tumour suppresor function, transcription factors and apop-
tosis – important for cervical cancer tumorigenesis.
Abstracts






ctober 25, 2021 at B












.16 on 12 O
ctober 2021. D
ow
nloaded from
 
